ANAB Anaptysbio Inc

Price (delayed)

$31.1

Market cap

$853.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.32

Enterprise value

$541.64M

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients ...

Highlights
ANAB's EPS has surged by 89% year-on-year and by 71% since the previous quarter
The net income has soared by 89% YoY and by 71% QoQ
The company's quick ratio fell by 28% QoQ

Key stats

What are the main financial stats of ANAB
Market
Shares outstanding
27.43M
Market cap
$853.18M
Enterprise value
$541.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.21
Price to sales (P/S)
8.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.35
Earnings
Revenue
$101.27M
EBIT
-$8.71M
EBITDA
-$7.4M
Free cash flow
$5.37M
Per share
EPS
-$0.32
Free cash flow per share
$0.2
Book value per share
$14.09
Revenue per share
$3.7
TBVPS
$15.57
Balance sheet
Total assets
$426.57M
Total liabilities
$40.84M
Debt
$20.78M
Equity
$385.73M
Working capital
$377.45M
Liquidity
Debt to equity
0.05
Current ratio
19.31
Quick ratio
18.99
Net debt/EBITDA
42.13
Margins
EBITDA margin
-7.3%
Gross margin
100%
Net margin
-8.6%
Operating margin
-9.8%
Efficiency
Return on assets
-2.1%
Return on equity
-2.3%
Return on invested capital
-7.1%
Return on capital employed
-2.1%
Return on sales
-8.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANAB stock price

How has the Anaptysbio stock price performed over time
Intraday
0.39%
1 week
9.08%
1 month
15.7%
1 year
11.35%
YTD
44.65%
QTD
14.68%

Financial performance

How have Anaptysbio's revenue and profit performed over time
Revenue
$101.27M
Gross profit
$101.27M
Operating income
-$9.89M
Net income
-$8.71M
Gross margin
100%
Net margin
-8.6%
ANAB's net margin has soared by 98% YoY and by 79% from the previous quarter
The company's operating margin has surged by 98% YoY and by 78% QoQ
The net income has soared by 89% YoY and by 71% QoQ
ANAB's operating income has surged by 89% year-on-year and by 69% since the previous quarter

Growth

What is Anaptysbio's growth rate over time

Valuation

What is Anaptysbio stock price valuation
P/E
N/A
P/B
2.21
P/S
8.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.35
ANAB's EPS has surged by 89% year-on-year and by 71% since the previous quarter
ANAB's P/B is 47% higher than its last 4 quarters average of 1.5 but 40% lower than its 5-year quarterly average of 3.7
The stock's price to sales (P/S) is 94% less than its 5-year quarterly average of 147.9 and 26% less than its last 4 quarters average of 11.4
ANAB's revenue is up by 42% from the previous quarter

Efficiency

How efficient is Anaptysbio business performance
ANAB's return on sales has surged by 98% year-on-year and by 79% since the previous quarter
The ROA has soared by 89% YoY and by 72% QoQ
Anaptysbio's return on equity has surged by 89% YoY and by 71% QoQ
The return on invested capital has surged by 81% year-on-year and by 67% since the previous quarter

Dividends

What is ANAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANAB.

Financial health

How did Anaptysbio financials performed over time
The company's total liabilities has surged by 182% QoQ and by 101% YoY
The company's quick ratio fell by 28% QoQ
ANAB's debt is 95% less than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.